---
document_datetime: 2024-08-30 14:31:38
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/saphnelo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: saphnelo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.0777739
conversion_datetime: 2025-12-20 01:53:14.71662
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Saphnelo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| IB/0019              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 29/08/2024                          | n/a                                         |                                  |                                                                                                                        |
| PSUSA/10980 /202307  | Periodic Safety Update EU Single assessment - anifrolumab                                                                                     | 21/03/2024                          | 16/05/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             | PSUSA/10980/202307.                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------|
| IB/0015   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/03/2024 | 16/05/2024 | SmPC and PL |                                                   |
| IA/0014   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/01/2024 | 16/05/2024 | SmPC        |                                                   |
| IB/0012/G | This was an application for a group of variations. B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile) B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 24/10/2023 | n/a        |             |                                                   |
| IB/0011   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/09/2023 | n/a        |             |                                                   |
| II/0007   | Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14/09/2023 | 16/05/2024 | SmPC and PL | Patients who completed D3461C00004 [study 04] and |

<div style=\"page-break-after: always\"></div>

|                     | based on final results from study D3461C00009 listed as an additional pharmacovigilance activity in the RMP; this is a multicentre, randomised, double- blind, placebo-controlled Phase III extension study to characterise the long-term safety and tolerability of anifrolumab in adult subjects with active systemic lupus erythematosus. In addition, the MAH took the opportunity to implement minor changes to sections 4.2 and 6.6 of the SmPC and to the Package Leaflet. In addition, the MAH took the opportunity to update the list of local representatives in the Netherlands in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                 | study D3461C00005 [study 05] (feeder trials) through Week 52 were eligible to continue on treatment in a randomised, double-blind, placebo-controlled, 3-year Long Term Extension (study D3461C00009). Following long-term observations, the clearance of anifrolumab was found to be stable in years 2 through 4 on treatment. Long-term efficacy was evaluated in patients who received anifrolumab 300 mg or placebo in a feeder trial and continued to receive the same treatment in the LTE (anifrolumab N=257; placebo N=112). Of these, 69% of patients who received anifrolumab (177/257) and 46% of patients who received placebo (52/112) completed a total of 4 years on treatment. At Week 208, the mean SLEDAI- 2K score (SE) was 3.4 (0.25) and 4.0 (0.46) in patients who received anifrolumab (n=140) and placebo (n=44) respectively. The overall long-term safety profile of anifrolumab was consistent with the 52 week trials. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10980 /202301 | Periodic Safety Update EU Single assessment - anifrolumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/08/2023 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0010           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/07/2023 | 16/05/2024 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0008             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/03/2023 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |    |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10980 /202207 | Periodic Safety Update EU Single assessment - anifrolumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/03/2023 | n/a        |    | PRAC Recommendation - maintenance |
| IB/0005             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 21/12/2022 | n/a        |    |                                   |
| IA/0006/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 19/12/2022 | n/a        |    |                                   |
| N/0004              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/10/2022 | 16/05/2024 | PL |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0002   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation   | 05/05/2022   | n/a   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0001   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation             | 11/04/2022   | n/a   |